Relationships of Prescription Opioid Sales to Opiate Treatment Admissions and Overdose Deaths: A Reanalysis of Relationships -- United States 2010-2019

Larry Aubry and B. Thomas Carr

Corresponding Author:

B. Thomas Carr

Carr Consulting

1215 Washington Avenue

Suite 201

Wilmette, IL 60091 USA

Email: Tom.Carr@CarrConsulting.net

Relationships of Prescription Opioid Sales to Opiate Treatment Admissions and Overdose Deaths: A Reanalysis of Relationships – United States 2010-2019

Larry Aubry and B. Thomas Carr

ABSTRACT

Background: In 2016, the United States Centers for Disease Control and Prevention (CDC) issued “CDC Guideline for Prescribing Opioids for Chronic Pain”. The guideline used data from 1999 to 2010 that related Opioid Sales to Opiate Treatment Admissions (a measure of drug addiction rates) Opioid Deaths. The CDC’s analysis indicated that opioid prescriptions are directly correlated¹⁻⁸ with drug addiction and overdose mortality outcomes. As a result, prescription opioid sales have been curtailed, making it difficult for sufferers of severe chronic pain to access an effective treatment option. In this paper, the relationships between opioid sales, drug addiction, and opioid deaths are reexamined using data from 2010 to 2019.

Methods: Linear regression models were fit to each response separately. Opioid sales (measured as MME per capita) was the independent variable. Total overdose deaths (TOD), any opioid overdose deaths (AOD), prescription opioid overdose deaths (POD) and opiate treatment admissions (OTA) were the dependent, response variables. The models were assessed using three criteria: the statistical significance of the model (Overall P-Value), the quality of the fit (R^2), and the sign of the slope coefficient.

Results: The analyses revealed that the direct correlations (significant, positive slopes) reported by the CDC based on data from 1999 to 2010 no longer exist based on data from 2010 to 2019. The relationships either have reversed (i.e., significant negative slopes) or are non-existent (no significant model).

Conclusions: The basis for the CDC guideline no longer holds. The guideline should be updated or annulled based on the current relationships that have existed for a decade. This is especially relevant for people suffering from severe, chronic pain, whose access to prescription opioids has been severely curtailed under the current guideline and to ensure that government resources are directed to an effective approach to reducing overdose deaths.

BACKGROUND AND RATIONALE

In 2015, the U.S. Department of Health and Human Services (HHS) declared “There is a clear correlation between opioid prescribing rates and overdose death rates in the United

States.”⁹ Direct correlations that existed between Total Overdose Deaths (TOD), Any Opioid Deaths (AOD), Prescription Opioid Deaths (POD), Opiate Treatment Admissions (OTA) and prescription opioid sales (POS) from 1999-2010 (see Figure 1) led the CDC to conclude that prescribed opioids are the determinant for overdose deaths and opiate/opioid treatment admissions.¹⁻⁸ Since the 2016 “CDC Guideline for Prescribing Opioids for Chronic Pain” (guideline), cutting prescription opioid sales has been CDC’s, DEA’s, legislative policy makers’, and practitioners’ solution to cut overdose deaths and opiate treatment admissions.¹⁰⁻¹²

*** Place Figure 1 Approximately Here ***

The impact of the CDC guideline has been systemic. Long term opioid therapy patients are not accepted as new patients by over 40% of primary pain clinics.¹² Projected cuts to opioid Rx MME per capita will result in 2020 values falling close to levels prescribed in 2000 of 298¹³ while the over 55 population has increased by 40 million. The American Medical Association (AMA) reports “the CDC Guideline has harmed patients”¹⁴, “72% of pain medicine specialists said that they—or their patients—have been required to reduce the quantity or dose of medication they have prescribed”¹⁴ as a result of the guideline.

“Almost 18 million Americans are currently taking long-term prescription opioids”¹⁵ to treat chronic pain. A “Health and Human Services Pain Management Best Practices Inter-Agency Task Force has determined that tens of millions of Americans rely on legal prescription opioids to treat acute or severe chronic pain, including pain arising from cancer as well as terminal or degenerative illnesses. The Food and Drug Administration (FDA) long ago approved opioid medications for these purposes, and doctors throughout the country lawfully prescribe them.”¹⁶ 92% of physicians and patients believe that opioids reduce pain and 57% report better quality of life.¹⁷

With drug overdose deaths “growing, inexorably and exponentially, for four decades”¹⁸ to a record 93,000 in 2020; FY2019 federal funding to combat the opioid crisis increasing to a record \$7.6 billion¹⁹ and “drug overdoses are now costing the United States approximately \$1 trillion annually”,²⁰ it is critical that public health policy guidance not be based on out-of-date and/or misleading information.

The present paper updates correlations between POS to OTA, POD, AOD and TOD from 2010 to 2019 and shows that the direct relationships that existed from 1999 to 2010 are no

longer present -- in fact, in some instances the relationships have reversed. Consequently, we find that continuing the policies of cutting prescription opioid sales to reduce TOD, AOD, POD, and OTA is unfounded.

METHODS:

DESCRIPTION OF DATA SOURCES:

Data Limitations: The authors acknowledge that the data reported by CDC and other sources necessarily contains inaccuracies. It is widely understood that it is impossible to ascertain the specific cause of an overdose death in all cases. This may be due, for example, to poly drug use with alcohol, and an inability to reliably determine the source of opioids detected in postmortem blood toxicity screens (e.g., prescription vs. illicit), among other confounding issues.^{21,22} However, the authors have employed the same data sources that CDC guideline appears to be based upon. As such, the results of analyses presented here are at least as reliable as what the CDC would be able to obtain from their own analyses, if they chose to undertake them. Thus, the following sources have been applied.

Drug Overdose Deaths (National); Total Overdose Deaths, Any Opioid Overdose Deaths and Prescription Opioid Overdose Deaths²³: 1999-2019 data accessed from Drugabuse.gov., Published 2021. Accessed January 10, 2021 from https://www.drugabuse.gov/sites/default/files/Overdose_data_1999-2019.xlsx

Opioid Overdose Death Crude Rates (U.S. States)²⁴: 1999-2019 data accessed from CDC, National Center for Health Statistics. Underlying Cause of Death, 1999-2019 were sourced from CDC WONDER Online Database, released in 2020. Data are from the Multiple Cause of Death Files, 1999-2019, as compiled from data provided by 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Identified using underlying cause-of-death codes X40–X44, X60–X64, X85, and Y10–Y14. Accessed Feb 7, 2021, 12:01:39 PM from <http://wonder.cdc.gov/ucd-icd10.html>

Opiate/Opioid Treatment Admissions (National)²⁵: 2006-2008 data accessed from Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, “Treatment Episode Data Set (TEDS): 2000-2010”. National Admissions

to Substance Abuse Treatment Services. DASIS Series S-61, HHS Publication No. (SMA) 12-4701. Rockville, MD: Substance Abuse and Mental Health Services Administration (samhsa.gov), 2012. p.43. Accessed April 18, 2021 from [Treatment Episode Data Set \(TEDS\) 2000 - 2010 \(samhsa.gov\)](#)

Opiate/Opioid Treatment Admissions (National)²⁶: 2008-2018 data accessed from Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, “Treatment Episode Data Set (TEDS): 2018.” Admissions to and Discharges from Publicly Funded Substance Use Treatment. Rockville, MD: 2018 TEDS Annual Report. Substance Abuse and Mental Health Services Administration (samhsa.gov), 2020. Table 1.1a. Accessed April 18, 2021 from https://www.samhsa.gov/data/sites/default/files/reports/rpt31097/2018_TEDS/2018_TEDS.html#PSU. [2018 TEDS Annual Report \(samhsa.gov\)](#)

Opioid Prescribing; MME per Capita (National)²⁷: 2006-2013 data accessed from CDC, “Annual Surveillance Report of Drug-Related Risks and Outcomes — United States Surveillance Special Report”. 2019 CDC, U.S. Department of Health and Human Services. Published November 1, 2019. p.115. Accessed January 10, 2021 from <https://www.cdc.gov/drugoverdose/pdf/pubs/2019-cdc-drug-surveillance-report.pdf>

Opioid Prescribing; MME per Capita (National)²⁸: 2014-2018 data accessed from Statista, “Annual morphine milligram equivalents (MME) dispensed per capita in the U.S. from 2014 to 2018”, MME per capita U.S. 2014-2018. Statista. May 28, 2021. Accessed July 8, 2021 from <https://www.statista.com/statistics/753284/number-of-mme-dispensed-per-capita-in-us/>.

Opioid Prescribing; MME per Capita (National)²⁹: 2019 data accessed from The IQVIA Institute, “Prescription Opioid Trends in the United States”, Institute Report, Dec 16, 2020. p.4. Accessed January 10, 2021 from <https://www.iqvia.com/insights/the-iqvia-institute/reports/prescription-opioid-trends-in-the-united-states>.

Opioid Prescribing; Opioid Dispensing Rates per 100 (U.S. States)³⁰: 2006-2019 data accessed from CDC, “U.S. Opioid Dispensing Rate Maps, Drug Overdose”, CDC Injury Center. Accessed February 9, 2021 from <https://www.cdc.gov/drugoverdose/rxrate->

[maps/index.html](#)

Opioid Sales kg/10,000 (National): For the period from 2006 through 2018/2019, these data were not known to be publicly available. We instead examined Opioid Prescribing by separately computing MME per Capita.

STATISTICAL METHODOLOGY:

Objective 1: Evaluate MME per Capita as a legitimate alternative measure of Annual Prescription Opioid Sales: The CDC used Annual Prescription Opioid Sales to support their current guideline (Figure 1). Data on Annual Prescription Opioid Sales are not readily available since 2010. However, MME per Capita data are available from 2006 to 2019 and offer a reasonable surrogate. Annual Sales data from the CDC chart were visually extracted and correlated with MME per Capita data, using simple linear regression analysis. The goal of the analysis was to evaluate MME per Capita as a legitimate alternative measure of Annual Prescription Opioid Sales.

Objective 2: Assess the strength and nature of the relationships between total overdose deaths (TOD), any opioid overdose deaths (AOD), prescription opioid overdose deaths (POD) and opiate treatment admissions (OTA) and Opioid Sales/MME per Capita: Consistent with the methods used by the CDC, simple linear regression models were fit to the data. Separate models were fit to each of the four dependent variables (TOD, AOD, POD, and OTA) using Annual Opioid Sales (i.e., MME per Capita) as the independent variable. Two models were fit to each dependent variable. One model covered the years presented in the original CDC chart (for which MME per Capita data were available) (2006-2010) and the second model covered the years since the published CDC chart (2010-2019).

For both objectives, the strength and nature of relationships in all the regression models were assessed using three criteria:

- 1) significance of the regression model (overall P-Value),
- 2) the quality of the model's fit (R^2), and

3) the sign of the linear slope coefficient (+ or -).

All models were fit using PROC REG from SAS/STAT software Version 9.4.

RESULTS AND DISCUSSION

Data from CDC's original chart was reconstructed using graphical analysis. The reconstructed Annual Prescription Opioid Sales values from the original CDC chart are highly correlated with publicly available MME per Capita values ($R^2 = 94\%$), which are available for more recent years than the sales data used by the CDC. MME per Capita is thus used in place of Annual Prescription Opioid Sales for all subsequent analyses.

For the years covered in the CDC's original chart (for which MME per Capita data are available, i.e., 2006-2010), the CDC's claim of positive/direct relationships between TOD, AOD, POD, and OTA and Annual Prescription Opioid Sales (i.e., MME per Capita) were validated ($91\% < R^2 < 97\%$), with statistically significant, positive slopes.

For more recent years (i.e., 2010-2019), however, the CDC's assertion of continued direct relationships is not valid. The relationships between TOD, AOD, POD, and OTA and Annual Prescription Opioid Sales (i.e., MME per Capita) are either non-existent or significantly negative/inverse (Figures 2 and 3).

*** Place Figure 2 Approximately Here ***

*** Place Figure 3 Approximately Here ***

National trends since 2010 are paralleled in a strong majority of states. Between 2010 and 2019 inclusive, there was a statistically significant negative correlation (95% confidence level) between AOD and Annual Prescription Opioid Sales in 40 states, with significant positive correlations occurring in only 2 states. Eight (8) states did not exhibit a significant (95% confidence level) relationship between overdose deaths and prescription opioid sales during the 2010-2019 time period.

Results for all regression models are presented in Table 1.

*** Place Table 1 Approximately Here ***

CONCLUSIONS:

Starting in 2010 opioid MME per Capita (POS) does not have a “clear correlation”⁹ or move “in parallel”³ or “in lockstep”² with OTA, POD, AOD or TOD. The relationship changed from direct to inverse.

From a peak in 2010 to 2019, POS decreased by over 50%. If POS were the root cause, correlated to and resulted in “parallel” or “lockstep” movements in POD, AOD, OTA, and TOD, then the result should have been an equivalent percentage reduction in these metrics. From 2010 to 2019, POD should have been 6,800 in 2019 instead of ending the decade flat at 14,139; AOD should have been 9,900 instead of increasing by 2.5x to 49,860; OTA should have been less than 210,000 in 2018 instead of increasing by 1.6x to 650,212 and TOD should be 17,900 instead of doubling to 70,630.

Data from the National Health Interview Survey (NHIS) demonstrate that between 2011 to 2016, while MME per capita declined by 21.8%, the amount of pain reported by Americans significantly increased. Incidence of high impact chronic pain increased by 84.9%, from 4.8 percent (10.6 million people, 1 in 20)³¹ to 8.0% of U.S. adults (19.6 million, 1 in 12.5)³². Incidence of patients afflicted with chronic pain increased by 67.2% from 13.6 percent (29.9 million, 1 in 7.4)³¹ to 20.4% (50.0 million, 1 in 5)³² of the U.S. adult population.

In light of the evidence presented in this paper, it should be recognized that the basis for the 2016 guideline is no longer valid. The guideline and associated content should be updated or annulled based on the current relationships that have existed for a decade, to eliminate the unnecessary suffering of individuals with chronic pain and to avoid the wasteful and ineffective spending patterns the government is executing based on the out-of-date guideline.

Source of Funding: None.

Author Disclosures: The authors report no relationship or financial interest with any entity that would pose a conflict of interest concerning the subject matter of this paper.

References:

1. CDC Press Releases. (2016, January 1). CDC.
<https://www.cdc.gov/media/releases/2016/p0315-prescribing-opioids-guidelines.html>
2. NCIPC Board of Scientific Counselors. "Draft Meeting Minutes" Department of Health and Human Services Public Health Service Board of Scientific Counselors (BSC), Centers for Disease Control and Prevention (CDC), National Center for Injury Prevention and Control (NCIPC) Eighteenth Meeting: Thursday, January 28, 2016: p.9.
https://www.cdc.gov/injury/pdfs/bsc/NCIPC_BSC_01_28_2016_Minutes_Final_3_15_2016.pdf.
3. CDC Guideline for Prescribing Opioids for Chronic Pain -United States, 2016 Morbidity and Mortality Weekly Report. (2016): p.2.
<https://www.cdc.gov/mmwr/volumes/65/rr/pdfs/rr6501e1.pdf>
4. Vital Signs: Overdoses of Prescription Opioid Pain Relievers --- United States, 1999--2008. Published 2019. <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6043a4.htm>
5. Haegerich, T. (2018). The Opioid Overdose Epidemic in the United States NCIPC/CDC Research Priorities: p.34. https://www.cdc.gov/injury/pdfs/bsc/Opioid-Research-Priorities_BSCJune2018_Haegerich-a.pdf
6. Noonan, R. (2016). Understanding and Addressing the Opioid Crisis Nevada's Prescription Drug Abuse Summit CDC PERSPECTIVE: p.8.
<https://dpbh.nv.gov/uploadedFiles/dpbh.nv.gov/content/Programs/ClinicalSAPTA/Meetings/5%20%20Rise%20of%20Heroin%20Rita%20Noonan.pdf>
7. Kolodny, A. (n.d.). Statement by:p.1,2.
<https://docs.house.gov/meetings/IF/IF14/20180228/106915/HHRG-115-IF14-Wstate-KolodnyA-20180228.pdf>
8. Bacon S. CDC's Approach to Addressing the Opioid Overdose Epidemic.; 2016: p.7.
https://www.ncsl.org/portals/1/documents/health/InjuryMtg2016_SBacon.pdf

9. ASPE ISSUE BRIEF.; 2015. Accessed January 25, 2022: p.5.
https://aspe.hhs.gov/sites/default/files/migrated_legacy_files/56406/ib_OpioidInitiative.pdf
10. Dasgupta, N., Beletsky, L., & Ciccarone, D. (2018). Opioid Crisis: No Easy Fix to Its Social and Economic Determinants. *American journal of public health*, 108(2), 182–186.
<https://doi.org/10.2105/AJPH.2017.304187>
11. Chen, Q., Larochelle, M. R., Weaver, D. T., Lietz, A. P., Mueller, P. P., Mercaldo, S., Wakeman, S. E., Freedberg, K. A., Raphael, T. J., Knudsen, A. B., Pandharipande, P. V., & Chhatwal, J. (2019). Prevention of Prescription Opioid Misuse and Projected Overdose Deaths in the United States. *JAMA network open*, 2(2), e187621.
<https://doi.org/10.1001/jamanetworkopen.2018.7621>
12. Lagisetty, P., et al. Improving Access to Primary and Pain Care for Patients Taking Opioids for Chronic Pain in Michigan: Recommendations from an Expert Panel. (2021): p.3.
<https://doi.org/10.7302/1699>
13. IQVIA, “Prescription Opioid Trends in the United States. Measuring and understanding progress in the opioid crisis.” *Institute Report*. Dec 16, 2020. Accessed August 26, 2021. <https://www.iqvia.com/en/insights/the-iqvia-institute/reports/prescription-opioid-trends-in-the-united-states>
14. Majara, J.L. Docket No. CDC-2020-0029 Letter Dowell D, Dowell.; 2020. p.5,7
<https://searchlf.ama-assn.org/undefined/documentDownload?uri=%2Funstructured%2Fbinary%2Fletter%2FLETTERS%2F2020-6-16-Letter-to-Dowell-re-Opioid-Rx-Guideline.pdf>
15. Beth D Darnall, PhD, David Juurlink, MD, PhD, FRCPC, FAACT, FACMT, Robert D Kerns, PhD, Sean Mackey, MD, PhD, Brent Van Dorsten, PhD, Keith Humphreys, PhD, Julio A Gonzalez-Sotomayor, MD, Andrea Furlan, MD, PhD, Adam J Gordon, MD, MPH, FACP, DFASAM, CMRO, Debra B Gordon, RN, DNP, FAAN, Diane E Hoffman, JD, MS, Joel Katz, PhD, CPsych, FCAHS, Stefan G Kertesz, MD, MSc, Sally Satel, MD, Richard A Lawhern, PhD, Kate M Nicholson, JD, Rosemary C Polomano, PhD, RN, FAAN, Owen D Williamson, FFPMANZCA, FRCSC Pain Medicine, Heath McAnally, MD, MSPH, Ming-Chih Kao, PhD, MD,

CIPS, Stephan Schug, MD, FANZCA, FFPMANZCA, EDPM, Robert Twillman, PhD, FACLP, Terri A Lewis, PhD, NCC, Richard L Stieg, MD, MHS, Kate Lorig, DrPH, Theresa Mallick-Searle, MS, APRN, Robert W West, PhD, Sarah Gray, PsyD, Steven R Ariens, RPh, PD, Jennifer Sharpe Potter, PhD, MPH, Penney Cowan, Chad D Kollas, MD, FACP, FAAHPM, Danial Laird, MD, JD, Barby Ingle, J Julian Grove, MD, Marian Wilson, PhD, MPH, RN-BC, Kashelle Lockman, PharmD, MA, Fiona Hodson, RN, DipAPPSci, Carol S Palackdharry, MD, MS, FACP, Roger B Fillingim, PhD, Jeffrey Fudin, PharmD, DAIPM, FCCP, FASH, FFSMB, Jennifer Barnhouse, Ajay Manhapra, MD, Steven R Henson, MD, Bruce Singer, PhD, Marie Ljosenvoor, PharmD, Marlisa Griffith, RN, Jason N Doctor, PhD, Kimeron Hardin, PhD, ABPP, FACHP, Cathleen London, MD, Jon Mankowski, CA, LCSW, Andrea Anderson, Linda Ellsworth, FNP-C, Lisa Davis Budzinski, Becky Brandt, RN, Greg Hartley, PT, DPT, Debbie Nickels Heck, MD, Mark J Zobrosky, Celeste Cheek, PT, DPT, Megan Wilson, Cynthia E Laux, RN, Geralyn Datz, PhD, Justin Dunaway, PT, DPT, Eileen Schonfeld, RN, Chaplain, Melissa Cady, DO, Thérèse LeDantec-Boswell, Meredith Craigie, MD, FFPMANZCA, FANZCA, John Sturgeon, PhD, Pamela Flood, MD, Melita Giummarra, PhD, Jessica Whelan, MSN, FPMHNP-BC, Beverly E Thorn, PhD, Richard L Martin, Michael E Schatman, PhD, Maurice D Gregory, MD, Joshua Kirz, PhD, Patti Robinson, PhD, James G Marx, MD, FASAM, Jessica R Stewart, Phillip S Keck, PhD, LCP, Scott E Hadland, MD, MPH, MS, Jennifer L Murphy, PhD, Mark A Lumley, PhD, Kathleen S Brown, PhD, Michael S Leong, MD, Mechele Fillman, MSN, NP, James W Broatch, MSW, Aaron Perez, PT, Kristine Watford, MD, Kari Kruska, RN (Retired), Dokyoung Sophia You, PhD, RN, Stacy Ogbeide, PsyD, MS, ABPP, Amy Kukucka, MSN, APRN, CHPN, FNP-C, Susan Lawson, PhD, LCSW, James B Ray, PharmD, CPE, T Wade Martin, MD, James B Lakehomer, PhD, Anne Burke, MPsy (clin), Dip Clin Hyp, Robert I Cohen, MD, MA, Peter Grinspoon, MD, Marc S Rubenstein, PT, DPT, Cert-APHPT, Stephani Sutherland, PhD (Neuroscience), Kristie Walters, RN (Retired), Travis Lovejoy, PhD, MPH, “International Stakeholder Community of Pain Experts and Leaders Call for an Urgent Action on Forced Opioid Tapering,” Pain Medicine, Volume 20, Issue 3, March 2019, Pages 429–433, <https://doi.org/10.1093/pm/pny228>

16. Walmart Inc., Plaintiff, v. U.S. Department of Justice; Attorney General William P. Barr; U.S. Drug Enforcement Administration; Acting Administrator Timothy J. Shea, Defendants. Case 4:20-cv-00817 Document 1 Filed 10/22/20. https://corporate.walmart.com/media-library/document/walmart-v-doj-dea-complaint/_proxyDocument?id=00000175-522e-dbe2-a9fd-7f6e94120000

17. Manchikanti, L., Kaye, A. M., Knezevic, N. N., McAnally, H., Slavin, K., Trescot, A. M., Blank, S., Pampati, V., Abdi, S., Grider, J. S., Kaye, A. D., Manchikanti, K. N., Cordner, H., Gharibo, C. G., Harned, M. E., Albers, S. L., Atluri, S., Aydin, S. M., Bakshi, S., & Barkin, R. L. (2017). Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines. *Pain Physician*, 20(2S), S3–S92. <https://pubmed.ncbi.nlm.nih.gov/28226332/>
18. Guzman, A. (n.d.). The Opioid Epidemic and the Practice of Medicine:p.12,13. https://www.deadiversion.usdoj.gov/mtgs/pract_awareness/conf_2019/dec_2019/guzman.pdf
19. Tracking FY2019 Federal Funding to Combat the Opioid Crisis | Bipartisan Policy Center. (n.d.). Bipartisanpolicy.org. <https://bipartisanpolicy.org/report/combating-the-opioid-crisis-2020/>
20. Commission on Combating Synthetic Opioid Trafficking. Commission on Combating Synthetic Opioid Trafficking: Final Report. Reports from the Commission on Combating Synthetic Opioid Trafficking (2022). Published online February 8, 2022. p.9 https://www.rand.org/pubs/external_publications/EP68838.html.
21. Peppin, J. F., & Coleman, J. J. (2021). CDC's Efforts to Quantify Prescription Opioid Overdose Deaths Fall Short. *Pain and therapy*, 10(1), 25–38. <https://doi.org/10.1007/s40122-021-00254-z>
22. Seth, P., Rudd, R. A., Noonan, R. K., & Haegerich, T. M. (2018). Quantifying the Epidemic of Prescription Opioid Overdose Deaths. *American journal of public health*, 108(4), 500–502. <https://doi.org/10.2105/AJPH.2017.304265>
23. (2021). Drugabuse.gov. https://www.drugabuse.gov/sites/default/files/Overdose_data_1999-2019.xlsx
24. Underlying Cause of Death, 1999-2019 Request. Cdc.gov. Published 2017. <https://wonder.cdc.gov/ucd-icd10.html>

25. Treatment Episode Data Set (TEDS) 2000 -2010 National Admissions to Substance Abuse Treatment Services. (n.d.). Retrieved December 17, 2021, from https://www.samhsa.gov/data/sites/default/files/2010_Treatment_Episode_Data_Set_National/2010_Treatment_Episode_Data_Set_National.pdf
26. 2018 TEDS Annual Report. www.samhsa.gov. Accessed December 17, 2021. https://www.samhsa.gov/data/sites/default/files/reports/rpt31097/2018_TEDS/2018_TEDS.html#PSU.
27. ANNUAL SURVEILLANCE REPORT OF DRUG-RELATED RISKS AND OUTCOMES. (2019). <https://www.cdc.gov/drugoverdose/pdf/pubs/2019-cdc-drug-surveillance-report.pdf>
28. MME per capita U.S. 2014-2018 | Statista. (n.d.). Statista. <https://www.statista.com/statistics/753284/number-of-mme-dispensed-per-capita-in-us/>
29. Prescription Opioid Trends in the United States. www.iqvia.com. <https://www.iqvia.com/insights/the-iqvia-institute/reports/prescription-opioid-trends-in-the-united-states>
30. U.S. Opioid Dispensing Rate Maps | Drug Overdose | CDC Injury Center. (2021, June 23). [Www.cdc.gov. https://www.cdc.gov/drugoverdose/rxrate-maps/index.html](https://www.cdc.gov/drugoverdose/rxrate-maps/index.html)
31. Prevalence and Profile of High Impact Chronic Pain.” NCCIH. <https://www.nccih.nih.gov/research/research-results/prevalence-and-profile-of-high-impact-chronic-pain>
32. Dahlhamer J, Lucas J, Zelaya, C, et al. Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults — United States, 2016. *MMWR Morbidity and Mortality Weekly Report*. 2018;67(36):1001-1006. DOI: <http://dx.doi.org/10.15585/mmwr.mm6736a2>

418

Table A1: Summary of Regression Models Fit in the Paper

Dependent Variable	Independent Variable	Years	Related Figure	n	R ²	P-Value	Slope	95% LCL	95%UCL	Interpretation
MME per Capita	Total Annual Prescription Opioid Sales	2006-2010	NA	5	0.94	0.006	141	76	206	Strong Model. Significant, Positive Relationship.
Total Overdose Deaths	MME per Capita	2006-2010	NA	5	0.97	0.002	20	14	26	Strong Model. Significant, Positive Relationship.
Any Opioid Overdose Deaths	MME per Capita	2006-2010	NA	5	0.99	0.000	20	17	24	Strong Model. Significant, Positive Relationship.
Prescription Opioid Deaths	MME per Capita	2006-2010	NA	5	0.97	0.002	15	10	20	Strong Model. Significant, Positive Relationship.
Opioid Treatment Admissions/1000	MME per Capita	2006-2010	NA	5	0.91	0.011	0.60	0.26	0.94	Strong Model. Significant, Positive Relationship.
Total Overdose Deaths	MME per Capita	2010-2019	Figure 3	10	0.89	0.000	-85	-109	-61	Strong Model. Significant, Negative Relationship.
Any Opioid Overdose Deaths	MME per Capita	2010-2019	Figure 3	10	0.92	0.000	-76	-95	-57	Strong Model. Significant, Negative Relationship.
Prescription Opioid Deaths	MME per Capita	2010-2019	Figure 3	10	0.03	0.615	-1.4	-7.4	4.7	No Model. Nonsignificant Relationship.
Opioid Treatment Admissions/1000	MME per Capita	2010-2018	Figure 3	9	0.89	0.000	-0.64	-0.84	-0.43	Strong Model. Significant, Negative Relationship.

419

420

Captions for Figures

Figure 1: CDC Chart 1999-2010, February 28, 2018, Congressional testimony “Combatting the Opioid Crisis.” made before the Committee on Energy & Commerce, Subcommittee on Health U.S. House of Representatives: “The CDC has shown that a sharp increase in prescriptions for opioids resulted in a corresponding rise in addiction and overdose deaths. This is a CDC graph. The green line represents opioid prescribing, the red line represents opioid deaths, and the blue line represents opioid addiction. The green line went up as opioid prescriptions started to soar, it led to parallel increases in addiction and overdose deaths.”⁷

Figure 2: 2010-2019 Update: The green line represents opioid prescribing (POS, MME/capita); the red lines are opioid deaths (POD, AOD & TOD); the blue line represents opioid addiction (OTA). Over the past decade, as the green line (prescription opioids) declined by +50%, prescription opioid deaths remained flat while opioid addiction, any opioid and total overdose deaths continued increasing “exponentially”⁸.

Figure 3: 2010-2019 Regression Models: Illustrates the regression of OTA, POD, AOD and TOD as functions of POS. Significant, negative relationships were found for OTA, AOD, and TOD. No significant relationship exists between POD and POS.

441 **Figure 1**

Source: CDC

442

Figure 2

Figure 3